QUOTE AND NEWS
Market Intelligence Center  Feb 25  Comment 
For a hedged play on Medicines Company (MDCO), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Apr. '15 $28.00 covered call for a net debit in the $26.96 area. That is also the break-even stock price for the covered...
GenEng News  Feb 4  Comment 
The Medicines Company said today it has completed its acquisition of Annovation Biopharma for an undisclosed price. The deal expands the buyer’s portfolio with Annovation compounds that include lead candidate ABP-700, an experimental...
FierceBiotech  Feb 4  Comment 
The Medicines Company bought out the shares of Annovation Biopharma it didn't already own, getting exclusive rights to a new anesthetic and scooping up a tiny biotech incubated by Atlas Venture.
Market Intelligence Center  Feb 2  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithm on Medicines Company (MDCO) could yield about 12.59% (27.84% annualized, for comparison purposes only) in 165 days. Pair a long position in the stock with the Jul. '15...
Market Intelligence Center  Jan 29  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithm on Medicines Company (MDCO) could yield about 3.74% (27.32% annualized, for comparison purposes only) in 50 days. Pair a long position in the stock with the Mar. '15...
FierceBiotech  Jan 23  Comment 
European regulators are recommending approval for The Medicines Company's cangrelor, setting up an overseas nod for a blood-thinning drug rejected by the FDA last year.
Benzinga  Jan 7  Comment 
KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) shares dipped 66.67% to $0.61 after the company reported top-line data from phase 2 study of KB001-A. LiqTech International, Inc. (NYSE: LIQT) shares fell 32.71% to $0.72. LiqTech International...




RELATED WIKI ARTICLES
 

Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki